Cargando…
One-Year Effects of Omega-3 Treatment on Fatty Acids, Oxylipins, and Related Bioactive Lipids and Their Associations with Clinical Lipid and Inflammatory Biomarkers: Findings from a Substudy of the Vitamin D and Omega-3 Trial (VITAL)
Omega-3 (n-3) treatment may lower cardiovascular risk, yet its effects on the circulating lipidome and relation to cardiovascular risk biomarkers are unclear. We hypothesized that n-3 treatment is associated with favorable changes in downstream fatty acids (FAs), oxylipins, bioactive lipids, clinica...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693376/ https://www.ncbi.nlm.nih.gov/pubmed/33120862 http://dx.doi.org/10.3390/metabo10110431 |
_version_ | 1783614729797763072 |
---|---|
author | Demler, Olga V. Liu, Yanyan Luttmann-Gibson, Heike Watrous, Jeramie D. Lagerborg, Kim A. Dashti, Hesam Giulianini, Franco Heath, Mallory Camargo, Carlos A. Harris, William S. Wohlgemuth, Jay G. Andres, Allen M. Tivari, Saumya Long, Tao Najhawan, Mahan Dao, Khoi Prentice, James G. Larsen, Julia A. Okereke, Olivia I. Costenbader, Karen H. Buring, Julie E. Manson, JoAnn E. Cheng, Susan Jain, Mohit Mora, Samia |
author_facet | Demler, Olga V. Liu, Yanyan Luttmann-Gibson, Heike Watrous, Jeramie D. Lagerborg, Kim A. Dashti, Hesam Giulianini, Franco Heath, Mallory Camargo, Carlos A. Harris, William S. Wohlgemuth, Jay G. Andres, Allen M. Tivari, Saumya Long, Tao Najhawan, Mahan Dao, Khoi Prentice, James G. Larsen, Julia A. Okereke, Olivia I. Costenbader, Karen H. Buring, Julie E. Manson, JoAnn E. Cheng, Susan Jain, Mohit Mora, Samia |
author_sort | Demler, Olga V. |
collection | PubMed |
description | Omega-3 (n-3) treatment may lower cardiovascular risk, yet its effects on the circulating lipidome and relation to cardiovascular risk biomarkers are unclear. We hypothesized that n-3 treatment is associated with favorable changes in downstream fatty acids (FAs), oxylipins, bioactive lipids, clinical lipid and inflammatory biomarkers. We examined these VITAL200, a nested substudy of 200 subjects balanced on demographics and treatment and randomly selected from the Vitamin D and Omega-3 Trial (VITAL). VITAL is a randomized double-blind trial of 840 mg/d eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) vs. placebo among 25,871 individuals. Small polar bioactive lipid features, oxylipins and FAs from plasma and red blood cells were measured using three independent assaying techniques at baseline and one year. The Women’s Health Study (WHS) was used for replication with dietary n-3 intake. Randomized n-3 treatment led to changes in 143 FAs, oxylipins and bioactive lipids (False Discovery Rate (FDR) < 0.05 in VITAL200, validated (p-values < 0.05)) in WHS with increases in 95 including EPA, DHA, n-3 docosapentaenoic acid (DPA-n3), and decreases in 48 including DPA-n6, dihomo gamma linolenic (DGLA), adrenic and arachidonic acids. N-3 related changes in the bioactive lipidome were heterogeneously associated with changes in clinical lipid and inflammatory biomarkers. N-3 treatment significantly modulates the bioactive lipidome, which may contribute to its clinical benefits. |
format | Online Article Text |
id | pubmed-7693376 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76933762020-11-28 One-Year Effects of Omega-3 Treatment on Fatty Acids, Oxylipins, and Related Bioactive Lipids and Their Associations with Clinical Lipid and Inflammatory Biomarkers: Findings from a Substudy of the Vitamin D and Omega-3 Trial (VITAL) Demler, Olga V. Liu, Yanyan Luttmann-Gibson, Heike Watrous, Jeramie D. Lagerborg, Kim A. Dashti, Hesam Giulianini, Franco Heath, Mallory Camargo, Carlos A. Harris, William S. Wohlgemuth, Jay G. Andres, Allen M. Tivari, Saumya Long, Tao Najhawan, Mahan Dao, Khoi Prentice, James G. Larsen, Julia A. Okereke, Olivia I. Costenbader, Karen H. Buring, Julie E. Manson, JoAnn E. Cheng, Susan Jain, Mohit Mora, Samia Metabolites Article Omega-3 (n-3) treatment may lower cardiovascular risk, yet its effects on the circulating lipidome and relation to cardiovascular risk biomarkers are unclear. We hypothesized that n-3 treatment is associated with favorable changes in downstream fatty acids (FAs), oxylipins, bioactive lipids, clinical lipid and inflammatory biomarkers. We examined these VITAL200, a nested substudy of 200 subjects balanced on demographics and treatment and randomly selected from the Vitamin D and Omega-3 Trial (VITAL). VITAL is a randomized double-blind trial of 840 mg/d eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) vs. placebo among 25,871 individuals. Small polar bioactive lipid features, oxylipins and FAs from plasma and red blood cells were measured using three independent assaying techniques at baseline and one year. The Women’s Health Study (WHS) was used for replication with dietary n-3 intake. Randomized n-3 treatment led to changes in 143 FAs, oxylipins and bioactive lipids (False Discovery Rate (FDR) < 0.05 in VITAL200, validated (p-values < 0.05)) in WHS with increases in 95 including EPA, DHA, n-3 docosapentaenoic acid (DPA-n3), and decreases in 48 including DPA-n6, dihomo gamma linolenic (DGLA), adrenic and arachidonic acids. N-3 related changes in the bioactive lipidome were heterogeneously associated with changes in clinical lipid and inflammatory biomarkers. N-3 treatment significantly modulates the bioactive lipidome, which may contribute to its clinical benefits. MDPI 2020-10-27 /pmc/articles/PMC7693376/ /pubmed/33120862 http://dx.doi.org/10.3390/metabo10110431 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Demler, Olga V. Liu, Yanyan Luttmann-Gibson, Heike Watrous, Jeramie D. Lagerborg, Kim A. Dashti, Hesam Giulianini, Franco Heath, Mallory Camargo, Carlos A. Harris, William S. Wohlgemuth, Jay G. Andres, Allen M. Tivari, Saumya Long, Tao Najhawan, Mahan Dao, Khoi Prentice, James G. Larsen, Julia A. Okereke, Olivia I. Costenbader, Karen H. Buring, Julie E. Manson, JoAnn E. Cheng, Susan Jain, Mohit Mora, Samia One-Year Effects of Omega-3 Treatment on Fatty Acids, Oxylipins, and Related Bioactive Lipids and Their Associations with Clinical Lipid and Inflammatory Biomarkers: Findings from a Substudy of the Vitamin D and Omega-3 Trial (VITAL) |
title | One-Year Effects of Omega-3 Treatment on Fatty Acids, Oxylipins, and Related Bioactive Lipids and Their Associations with Clinical Lipid and Inflammatory Biomarkers: Findings from a Substudy of the Vitamin D and Omega-3 Trial (VITAL) |
title_full | One-Year Effects of Omega-3 Treatment on Fatty Acids, Oxylipins, and Related Bioactive Lipids and Their Associations with Clinical Lipid and Inflammatory Biomarkers: Findings from a Substudy of the Vitamin D and Omega-3 Trial (VITAL) |
title_fullStr | One-Year Effects of Omega-3 Treatment on Fatty Acids, Oxylipins, and Related Bioactive Lipids and Their Associations with Clinical Lipid and Inflammatory Biomarkers: Findings from a Substudy of the Vitamin D and Omega-3 Trial (VITAL) |
title_full_unstemmed | One-Year Effects of Omega-3 Treatment on Fatty Acids, Oxylipins, and Related Bioactive Lipids and Their Associations with Clinical Lipid and Inflammatory Biomarkers: Findings from a Substudy of the Vitamin D and Omega-3 Trial (VITAL) |
title_short | One-Year Effects of Omega-3 Treatment on Fatty Acids, Oxylipins, and Related Bioactive Lipids and Their Associations with Clinical Lipid and Inflammatory Biomarkers: Findings from a Substudy of the Vitamin D and Omega-3 Trial (VITAL) |
title_sort | one-year effects of omega-3 treatment on fatty acids, oxylipins, and related bioactive lipids and their associations with clinical lipid and inflammatory biomarkers: findings from a substudy of the vitamin d and omega-3 trial (vital) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693376/ https://www.ncbi.nlm.nih.gov/pubmed/33120862 http://dx.doi.org/10.3390/metabo10110431 |
work_keys_str_mv | AT demlerolgav oneyeareffectsofomega3treatmentonfattyacidsoxylipinsandrelatedbioactivelipidsandtheirassociationswithclinicallipidandinflammatorybiomarkersfindingsfromasubstudyofthevitamindandomega3trialvital AT liuyanyan oneyeareffectsofomega3treatmentonfattyacidsoxylipinsandrelatedbioactivelipidsandtheirassociationswithclinicallipidandinflammatorybiomarkersfindingsfromasubstudyofthevitamindandomega3trialvital AT luttmanngibsonheike oneyeareffectsofomega3treatmentonfattyacidsoxylipinsandrelatedbioactivelipidsandtheirassociationswithclinicallipidandinflammatorybiomarkersfindingsfromasubstudyofthevitamindandomega3trialvital AT watrousjeramied oneyeareffectsofomega3treatmentonfattyacidsoxylipinsandrelatedbioactivelipidsandtheirassociationswithclinicallipidandinflammatorybiomarkersfindingsfromasubstudyofthevitamindandomega3trialvital AT lagerborgkima oneyeareffectsofomega3treatmentonfattyacidsoxylipinsandrelatedbioactivelipidsandtheirassociationswithclinicallipidandinflammatorybiomarkersfindingsfromasubstudyofthevitamindandomega3trialvital AT dashtihesam oneyeareffectsofomega3treatmentonfattyacidsoxylipinsandrelatedbioactivelipidsandtheirassociationswithclinicallipidandinflammatorybiomarkersfindingsfromasubstudyofthevitamindandomega3trialvital AT giulianinifranco oneyeareffectsofomega3treatmentonfattyacidsoxylipinsandrelatedbioactivelipidsandtheirassociationswithclinicallipidandinflammatorybiomarkersfindingsfromasubstudyofthevitamindandomega3trialvital AT heathmallory oneyeareffectsofomega3treatmentonfattyacidsoxylipinsandrelatedbioactivelipidsandtheirassociationswithclinicallipidandinflammatorybiomarkersfindingsfromasubstudyofthevitamindandomega3trialvital AT camargocarlosa oneyeareffectsofomega3treatmentonfattyacidsoxylipinsandrelatedbioactivelipidsandtheirassociationswithclinicallipidandinflammatorybiomarkersfindingsfromasubstudyofthevitamindandomega3trialvital AT harriswilliams oneyeareffectsofomega3treatmentonfattyacidsoxylipinsandrelatedbioactivelipidsandtheirassociationswithclinicallipidandinflammatorybiomarkersfindingsfromasubstudyofthevitamindandomega3trialvital AT wohlgemuthjayg oneyeareffectsofomega3treatmentonfattyacidsoxylipinsandrelatedbioactivelipidsandtheirassociationswithclinicallipidandinflammatorybiomarkersfindingsfromasubstudyofthevitamindandomega3trialvital AT andresallenm oneyeareffectsofomega3treatmentonfattyacidsoxylipinsandrelatedbioactivelipidsandtheirassociationswithclinicallipidandinflammatorybiomarkersfindingsfromasubstudyofthevitamindandomega3trialvital AT tivarisaumya oneyeareffectsofomega3treatmentonfattyacidsoxylipinsandrelatedbioactivelipidsandtheirassociationswithclinicallipidandinflammatorybiomarkersfindingsfromasubstudyofthevitamindandomega3trialvital AT longtao oneyeareffectsofomega3treatmentonfattyacidsoxylipinsandrelatedbioactivelipidsandtheirassociationswithclinicallipidandinflammatorybiomarkersfindingsfromasubstudyofthevitamindandomega3trialvital AT najhawanmahan oneyeareffectsofomega3treatmentonfattyacidsoxylipinsandrelatedbioactivelipidsandtheirassociationswithclinicallipidandinflammatorybiomarkersfindingsfromasubstudyofthevitamindandomega3trialvital AT daokhoi oneyeareffectsofomega3treatmentonfattyacidsoxylipinsandrelatedbioactivelipidsandtheirassociationswithclinicallipidandinflammatorybiomarkersfindingsfromasubstudyofthevitamindandomega3trialvital AT prenticejamesg oneyeareffectsofomega3treatmentonfattyacidsoxylipinsandrelatedbioactivelipidsandtheirassociationswithclinicallipidandinflammatorybiomarkersfindingsfromasubstudyofthevitamindandomega3trialvital AT larsenjuliaa oneyeareffectsofomega3treatmentonfattyacidsoxylipinsandrelatedbioactivelipidsandtheirassociationswithclinicallipidandinflammatorybiomarkersfindingsfromasubstudyofthevitamindandomega3trialvital AT okerekeoliviai oneyeareffectsofomega3treatmentonfattyacidsoxylipinsandrelatedbioactivelipidsandtheirassociationswithclinicallipidandinflammatorybiomarkersfindingsfromasubstudyofthevitamindandomega3trialvital AT costenbaderkarenh oneyeareffectsofomega3treatmentonfattyacidsoxylipinsandrelatedbioactivelipidsandtheirassociationswithclinicallipidandinflammatorybiomarkersfindingsfromasubstudyofthevitamindandomega3trialvital AT buringjuliee oneyeareffectsofomega3treatmentonfattyacidsoxylipinsandrelatedbioactivelipidsandtheirassociationswithclinicallipidandinflammatorybiomarkersfindingsfromasubstudyofthevitamindandomega3trialvital AT mansonjoanne oneyeareffectsofomega3treatmentonfattyacidsoxylipinsandrelatedbioactivelipidsandtheirassociationswithclinicallipidandinflammatorybiomarkersfindingsfromasubstudyofthevitamindandomega3trialvital AT chengsusan oneyeareffectsofomega3treatmentonfattyacidsoxylipinsandrelatedbioactivelipidsandtheirassociationswithclinicallipidandinflammatorybiomarkersfindingsfromasubstudyofthevitamindandomega3trialvital AT jainmohit oneyeareffectsofomega3treatmentonfattyacidsoxylipinsandrelatedbioactivelipidsandtheirassociationswithclinicallipidandinflammatorybiomarkersfindingsfromasubstudyofthevitamindandomega3trialvital AT morasamia oneyeareffectsofomega3treatmentonfattyacidsoxylipinsandrelatedbioactivelipidsandtheirassociationswithclinicallipidandinflammatorybiomarkersfindingsfromasubstudyofthevitamindandomega3trialvital |